Cara Therapeutics Inc logo

Cara Therapeutics Inc

$ 12.32 -0.17 (-1.36%) 10:08 PM EST
P/E:
At Loss
P/B:
3.58
Market Cap:
$ 662.00M
Enterprise V:
$ 517.89M
Volume:
193.17K
Avg Vol (2M):
326.51K
Also Trade In:
Volume:
193.17K
Market Cap $:
662.00M
PE Ratio:
At Loss
Avg Vol (2-Month):
326.51K
Enterprise Value $:
517.89M
PB Ratio:
3.58
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Name Current Vs Industry Vs History
Cash-To-Debt 65.58
Equity-to-Asset 0.87
Debt-to-Equity 0.01
Debt-to-EBITDA -0.03
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.23
Distress
Grey
Safe
Beneish M-Score -4.21
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 67.73
9-Day RSI 69.9
14-Day RSI 68.28
6-1 Month Momentum % 9.03
12-1 Month Momentum % -24.38

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.63
Quick Ratio 6.56
Cash Ratio 5.52
Days Inventory 173.87
Days Sales Outstanding 62.09
Days Payable 590.51

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.6

Financials (Next Earnings Date:2023-03-01 Est.)

CARA's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:CARA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 39.427
EPS (TTM) ($) -1.66
Beta 0.58
Volatility % 52.03
14-Day RSI 68.28
14-Day ATR ($) 0.534431
20-Day SMA ($) 11.196
12-1 Month Momentum % -24.38
52-Week Range ($) 7.4 - 13.965
Shares Outstanding (Mil) 53.73

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cara Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Cara Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.